Find us on
Executive and Board of Directors
Jack Coats, CEO, Board Member
Jack Coats, Chief Executive Officer and Board Member, is an entrepreneur and senior manager with over 30 years of experience in medical device and medical imaging companies specializing in imaging, software, radiation oncology and nanotechnology characterization and commercialization. He has an MS in Physics from the University of Missouri and has completed an MBA executive course at the Wharton Business School of the University of Pennsylvania. As Vice President at Varian Medical Systems, Jack drove the development of the integrated systems solution and guided its highly successful market introduction. As President of Nucletron Corporation, he established a groundbreaking strategy to develop innovative products that enabled body-site specific treatments for breast, prostate, and rectal cancer. While at FEI Company, he led the NanoBiology group into a premier market position in characterization of nanomaterials in collaboration with the NIH/NCI—Nanotechnology Characterization Laboratory. He established Xradia as the nano imaging technology leader in osteoporosis research and developed a highly significant research trial with a major drug company. He started 3dMD and served as its President, building a lucrative surgical planning business. That led to the establishment of a medical imaging company that has a novel solution for image-guided radiation treatments called Vision RT, Ltd., where he is a Board Director.
Geoffrey Dalbow, Chief Technology Officer
Mr. Geoffrey Dalbow, Chief Technology Officer, is a proven executive and healthcare technology innovator with extensive experience in the research and development of imaging solutions for the detection and diagnosis of disease. Geoffrey was able to introduce breakthrough imaging and therapy technologies that transformed the way healthcare is practiced. Geoffrey has guided startups to IPO, and led acquisitions of symbiotic technologies to round out a product portfolio, so as to achieve first-to-market and often market-leading status.
Dr. Calvin Goforth, Board Member
Dr. Calvin Goforth has extensive experience in start-up company development including intellectual property assessment, building strong development teams, raising private and government funding, and bringing products to market. Early in his career, he held positions at NASA and Rocketdyne, served as an Assistant Professor in Mechanical Engineering at the University of Arkansas, and founded Vector, Inc. (to build open-architecture PC-based controllers), which he later sold. He is Founder and President of VIC, a technology venture development firm supporting the growth of promising early-stage technology companies.
Ramsay Ball, Board Member
Mr. Ramsay Ball is an executive broker and principal with Colliers International Arkansas, the state’s largest commercial real estate company. Mr. Ball manages an early-stage technology investment fund, Alpha Fund I, and an early-stage venture capital company, Cannon Capital. Mr. Ball is a member of Gravity Ventures Arkansas One and Gravity Ventures Arkansas Two, member-managed angel capital funds. He is also a member of the Natural State Angel Association and the Northwest Arkansas Entrepreneurial Alliance. Mr. Ball supports the entrepreneurial program at the University of Arkansas’ Sam M. Walton College of Business and is a mentor with the ARK Challenge, a mentorship-driven business accelerator program. He is a member of Accelerate Arkansas, a statewide group of business and education leaders committed to building a competitive, knowledge-based economy in Arkansas. Mr. Ball serves on the boards of Colliers International Arkansas, VIC Technology Venture Development, Biologics MD, BlueInGreen, SFC Fluidics, Sevo Nutraceuticals, Btiques, and Oh Baby Foods. He is also on the board of the Northwest Arkansas Community College Foundation, and is a manager of the VIC Growth Fund.
Stan Green, Board Member
Mr. Stan Green is Co-founder and President of Clear Energy, Inc. and Co-founder and President of Lindsey-Green Commercial Properties, LP. Clear Energy provides turnkey energy efficiency solutions for commercial and industrial facilities; Lindsey-Green develops, owns and manages commercial real estate. Mr. Green has more than 30 years of experience in corporate finance and business development for companies and clients in the energy industry. He helped build Southwestern Energy into a top independent energy company as its Chief Financial Officer, and then served as Director of Energy for Wal-Mart Stores Inc. Mr. Green managed all aspects of the retailer’s domestic energy budget, oversaw energy retrofits for existing Wal-Mart buildings, and was a team leader on initiatives to reduce greenhouse gas emissions and energy use. He managed Wal-Mart’s initiatives in deregulated electricity markets and developed innovative contract structures to lower procurement costs. Mr. Green has been a member of the Board for the NW AR Regional Airport Authority since 1993, having served as Chairman from 1995-2010. He has been a member of the Northwest Arkansas Council since 1993, was named to the Board for the University of Arkansas Technology Development Foundation in 2012, and has served on the Boards of both First State Bank and the Community Bank of Arkansas.
Scientific Advisory Board
Dr. Elliot McVeigh
Before joining the University of California, San Diego, Dr. Elliot McVeigh was chair of the Department of Biomedical Engineering at Johns Hopkins University, where he founded the Medical Imaging Laboratory. In 1999, Dr. McVeigh joined forces with the Laboratory of Cardiac Energetics at the National Institutes of Health to develop a research program in cardiovascular interventional MRI. Dr. McVeigh had been on the Johns Hopkins faculty since 1988, immediately after earning his Ph.D. in medical biophysics at the University of Toronto, where he also earned a bachelor’s in physics in 1984.
Dr. McVeigh is the co-director of the Center for Translational Imaging (CTI) and has a 30-year history of research in medical imaging, particularly cardiovascular MRI. Throughout that time he has worked in a collaborative environment with industry, engineering faculty, and physicians creating new ways to use cardiovascular imaging toward precise diagnosis and therapy for individual patients. He pioneered multiple applications of MRI tagging to characterize the mechanical consequences of local myocardial ischemia and dyssynchronous mechanical activation of the LV. Upon becoming chair of Hopkins BME he lead the growth and development of the Center for Bioengineering Innovation and Design from an undergraduate design course to a major center of activity for innovation and commercialization of products designed by teams of engineers at physicians at Johns Hopkins. While MRI was his focus in his early career, Dr. McVeigh turned to cardiac CT to provide the highest resolution functional analysis of the heart; and, along with Dr. Amir Pourmorteza developed SQuEEZ to measure and quantify heart wall motion. Dr. McVeigh’s lab continues to develop novel scanning and image analysis techniques in MRI and CT for individualized care of cardiovascular patients.
Dr. Amir Pourmorteza
Amir Pourmorteza, PhD, is an Assistant Professor in the Department of Radiology and Imaging Sciences at Emory University School of Medicine. Dr. Pourmorteza is a biomedical engineer and CT physicist specializing in cardiovascular imaging, spectral computed tomography, tomographic reconstruction, and artificial intelligence in medical imaging including the use of radiogenomics in cancer. Dr. Pourmorteza received his Master of Science in Electrical Engineering (Bioelectrics) from University of Tehran. He obtained his PhD in Biomedical Engineering and completed a Fellowship in Tomographic Reconstruction from Johns Hopkins University in Baltimore, Maryland. During his time at Johns Hopkins, he teamed with Dr. Elliot McVeigh, then Chairman of Biomedical Engineering, to develop the cardiac CT-based algorithm called SQuEEZ that precisely measures and quantifies heart wall motion, which is the key to diagnosis of patients with cardiovascular disease. His research is focused on bench-to-bedside translation and validation of novel imaging technologies with a special interest in spectral and high-resolution CT. Prior to joining Emory, he led the National Institute of Health photon-counting CT group where he carried out the first clinical studies of photon-counting CT.
Dr. Myron Weisfeldt
Dr. Myron Weisfeldt is University Distinguished Service Professor at Johns Hopkins School of Medicine following a 13-year tenure as Chair of the Department of Medicine at Johns Hopkins. He is currently business and investment consultant at Johns Hopkins and leads an international network performing research in man on resuscitation from cardiac arrest and severe traumatic injury.
Dr. Weisfeldt received a B.A. and MD from the Johns Hopkins University. He trained in Cardiology at the Massachusetts General Hospital and the National Institutes of Health. From 1991 to 2001, he was Chairman of the Department of Medicine and Samuel Bard Professor of Medicine at the Columbia University College of Physicians and Surgeons and Director of the Medical Service at the Columbia-Presbyterian Campus of the New York Presbyterian Hospital. From 1975 to 1991, he was Director of the Cardiology Division at the Johns Hopkins University School of Medicine. Dr. Weisfeldt was Chairman of the Cardiology Advisory Board of the National Heart Lung and Blood Institute from 1987 to 1990 and held the position of President of the American Heart Association in 1990. His research interests have included heart function, age changes in the heart and circulation, and cardiopulmonary resuscitation.
Dr Weisfeldt’s accomplishments include a major role in the first implantation of automatic implantable defibrillators in human beings. He was the senior project investigator for the study which led to the approval by the FDA of TPA to dissolve the clot causing acute myocardial infarction. He led the effort of the American Heart Association to develop and test the Automatic External Defibrillators for bystander use that are now seen in essentially all airports and many public locations in the United States. He was among the study leaders of the clinical trial that established the value of Public Access Defibrillation to increase survival from sudden cardiac arrest.
In 2003 he was appointed by the National Heart, Lung and Blood Institute to be the Study Chair for a large-scale ongoing clinical trials network to conduct randomized definitive trials of devices, drugs and other therapies for out-of-hospital cardiac arrest and severe traumatic injury. This network is in its 11th year and has additional support from the US Department of Defense, Canadian Health Agencies, Defense Canada, and the American Heart Association.